Introduction {#S1}
============

The most effective vaccines in use today rely on the long-term protection elicited by high-affinity memory B cells and long-lived plasma cells, which are associated with germinal centers (GC) ([@B1]). Follicular helper T (Tfh) cells, a newly discovered CD4^+^ T cell subset, can regulate humoral immune responses in the body and drive cells to migrate into peripheral lymphoid follicles. Tfh cells also help B cell proliferation and differentiation, the generation of GCs ([@B2]--[@B4]), and stimulate B cells to produce antibodies and promote antibody class switching ([@B5]). Therefore, Tfh cells are critical in GC formation and the production of high-affinity antibodies ([@B6]). B cell lymphoma 6 (Bcl-6), a Tfh cell-specific transcription factor, is a key regulator of Tfh cell differentiation and function ([@B7]). Bcl-6 induces the expression of the chemokine receptor CXCR5, a hallmark of Tfh cells, which promotes their migration into CXCL13 rich areas such as B cell follicles ([@B8]). The cytokine IL-21, secreted by Tfh cells, is a major factor in Tfh cell effector function. IL-21 functions by binding to the IL-21 receptor on the surface of B cells in the GC ([@B9]). Meanwhile, Tfh cells themselves express IL-21 receptors, thus affecting the differentiation and migration of Tfh cells via autocrine signaling ([@B10], [@B11]). Because of their central role in the production of long-lasting humoral immunity, Tfh cells represent an interesting target for rational vaccine design. Novel or modified adjuvants may prove to be an effective strategy for skewing helper T cell differentiation toward the Tfh cell subset and promoting GC responses. Type I interferons (IFN-I) represent a family of cytokines with antiviral and immunomodulatory activities ([@B12]). Researchers have previously identified IFN-I as a natural adjuvant that selectively supports the generation of lymph node resident Tfh cells ([@B13]). Our previous work revealed the potent adjuvant activity of IFN-α, which enhanced the generation of Tfh cells and regulated humoral immunity by promoting GC reactions and antibody responses ([@B14]).

Some studies have revealed that Tfh cells are capable of differentiating into memory cells. Memory Tfh cells strongly downregulated their signature Bcl- 6-, CXCR5-, and PD-1-encoding genes in the memory phase ([@B2], [@B15]). Upon rechallenge with antigen, they once more rapidly upregulated these markers. Memory Tfh cells retain their capacity to recall their Tfh-specific effector functions upon antigen reactivation to provide help for B cell responses, and therefore play an important role in prime and boost vaccination or during recall responses to infection ([@B16]). These findings have important implications for rational vaccine design, where improving the generation and engagement of memory Tfh cells could be used to enhance vaccine-induced protective immunity. Thus, it is critical to design rational prime and boost strategies for the optimal generation of Tfh memory cells.

Further research (in both humans and animal models) into precisely how we can manipulate memory Tfh cells to improve vaccine responses, may enable us to address some of the challenges currently facing the development of effective vaccines. The present study shows that IFN-α can promote the development of immune memory, including memory Tfh cells and memory B cells, in response to the foot-and-mouth disease vaccine, and thus promote rapid immune reactivation on repeated antigen exposure.

Materials and Methods {#S2}
=====================

Mice and Vaccination Regimens {#S2.SS1}
-----------------------------

A total of 6 to 8 weeks old female BALB/c mice (from Shanghai Xipuer-Beikai Experimental Animal Co., Ltd) were used in all immunization experiments. All mice were randomly divided into six groups (20 mice per group, 5 mice at each time point within group), respectively injected with 5 × 10^8^ TU/ml recombinant adenovirus rAd (reconstituted Adenovirus vector type 5), rAd5VP1 (VP1 is a one of envelop protein from Foot and Mouth Virus), rAd5poIFN-α (IFN-α reconstituted Adenovirus vector type 5), rAd5VP1 + rAd5poIFN-α (combined rAd5VP1 and rAd5poIFN-α), rAd5VP1-2A- poIFN-α (co-expression VP1 and poIFN-α reconstituted Adenovirus vector type 5), and FMDV inactivated vaccine (commercial vaccine). The animals received a booster infection 15 days after the initial immunization. Mice were harvested 30, 60, and 90 days after priming. In addition, the mice were immunized again the same way 90 days later, and the mice were harvested 3 days later.

Flow Cytometry Analysis {#S2.SS2}
-----------------------

Single cell suspensions of peripheral blood mononuclear cells (PBMCs) derived from the mouse spleen were stained for 30 min at 4°C with anti-mouse CD4 (RM4-5), anti-mouse CXCR5 (2G8), anti-mouse CD44 (IM7), anti-mouse CD62L (MEL-14), anti-mouse CXCR3 (CXCR3-173), anti-mouse CCR6 (140706), anti-mouse CD38 (90/CD38), anti-mouse B220 (RA3-6B2), anti-mouse GL-7 (GL7), anti-mouse IgG1 (A85-1), anti-mouse CD86 (GL1), anti-mouse Bcl-6 (K112-91), anti-mouse IL-21 (mhalx21), anti-mouse IFN-γ (XMG1.2), and anti-mouse IL-4 (11B11). All of the listed antibodies, with the exception of anti-mouse IL-21 (which was sourced from eBioscience), were purchased from BD Pharmingen. For the detection of intracellular factors by flow cytometry, PBMCs were stimulated with a combination of phorbol myristate acetate (PMA), ionomycin calcium salt, and monensin, prior to performing intracellular staining. Cell acquisition was performed on a FACSCelesta^TM^ Flow Cytometer (BD Biosciences).

Quantitative Real-Time PCR {#S2.SS3}
--------------------------

PBMC RNA was isolated with an RNAsimple Total RNA Kit according to the manufacturer's guidelines (TIANGEN) and reverse transcribed into cDNA using the First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). For the mRNA expression assays, the following probes were used (all from Applied Thermo Fisher Scientific): BCL-6, Mm00477633_m1; STAT1, Mm01257286_m1; and β-actin, Mm02619580_m1. The reactions were set up following manufacturer's guidelines and the mRNA expression was evaluated by real-time reverse transcription polymerase chain reaction (RT-PCR) analysis.

Enzyme-Linked Immunosorbent Assay (ELISA) {#S2.SS4}
-----------------------------------------

Mice serum was harvested after immunization. Total IgG, IgG1, IgG2a, and IgG2b were assayed using the mouse ELISA Kit (eBioscience), according to the manufacturer's instructions. Absorbance at 450 nm was measured using a spectrometer enzyme-labeled instrument (Bio-Rad).

Statistical Analysis {#S2.SS5}
--------------------

Flow cytometry results were analyzed using Flowjo software (Tree Star, Inc.). All statistical tests were performed using Prism 5 (GraphPad Software, Inc.). The results were expressed as means ± SD of the indicated number of experiments. *P* values were calculated using *t* tests or two-way ANOVA, with a 95% confidence interval. *P* values below 0.05 were considered statistically significant (^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001, and ^\*\*\*\*^*P* \< 0.0001).

Results {#S3}
=======

IFN-α Enhances the Generation of Memory Tfh Cells, Induced by Recombinant Adenoviruses {#S3.SS1}
--------------------------------------------------------------------------------------

Our previous work showed that porcine IFN-α potently enhanced the generation of Tfh cells induced by FMD recombinant adenovirus vaccines, and thus increased the expression of Bcl-6 mRNA and the secretion of IL-21 in the serum ([@B14]). It was revealed that Tfh cells are able to survive as memory cells, with the vast majority residing in the spleen and peripheral lymph nodes ([@B17]). To address whether IFN-α up-regulates the generation of memory Tfh cells, BALB/c mice were immunized with either adenoviral vectors expressing FMDV VP1 alone (rAd5VP1) or co-expressing VP1 and IFN-a (rAd5VP1-2A-poIFN-α). In addition, BALB/c mice were immunized simultaneously with adenoviral vectors expressing FMDV VP1 and those expressing porcine IFN-α. The splenocytes were harvested on days 30, 60, and 90 after immunization, and the activated CD4^+^ T cells, memory CD4^+^ T cells, and memory Tfh cells (CXCR5^+^CD4^+^) were enumerated and characterized by multiple-color flow cytometry. As shown in [Figures 1A--C](#F1){ref-type="fig"}, we found an marked increase in the frequency of activated CD4^+^ T cells, memory CD4^+^ T cells, and memory Tfh cells in mice immunized with recombinant adenoviruses, which was sustained for at least 90 days post immunization ([Figure 1E](#F1){ref-type="fig"}). The CCR7^*lo*^ Tfh cell subset provides a biomarker for monitoring protective antibody responses during infection or vaccination. Therefore, we subsequently quantified CCR7^*lo*^CXCR5^+^CD4^+^ T cells on days 30, 60, and 90 after immunization. We found that IFN-α enhanced the recombinant adenovirus-induced generation of CCR7^*lo*^CXCR5^+^CD4^+^ T cells ([Figure 1D](#F1){ref-type="fig"}), which was sustained for at least 90 days following immunization ([Figure 1E](#F1){ref-type="fig"}). The result confirmed that IFN-α enhances the generation of memory Tfh cells induced by recombinant adenoviruses. Bcl-6, a master regulator of Tfh cell generation, is required for Tfh memory cell maintenance and the subsequent establishment of humoral memory. To this end, we also monitored the intracellular expression of Bcl-6 in Tfh cells at day 90 after immunization, and found that splenic memory CXCR5^+^ Th cells expressed low levels of Bcl-6. However, Bcl-6 expression levels were significantly higher in these memory CXCR5^+^ Th cells than in their CXCR5^--^ Th cell counterparts. Similarly, we observed that IFN-α enhanced the expression levels of Bcl-6 in memory Tfh cells ([Figure 1F](#F1){ref-type="fig"}). It is therefore likely that Tfh memory cells, endowed with an enhanced potential to produce IL-21, paired with higher CXCR5 and lower CCR7 expression ([Figure 1G](#F1){ref-type="fig"}), should enable this unique subset of Th cells to provide more efficient help for antigen-specific B cells than their non-Tfh counterparts.

![IFN-a enhances the generation of memory Tfh cells. **(A--D)** Thirty days after the immunization, representative dot plot from flow cytometric analysis of CD44^+^CD4^+^ T cells, CD62L^-^CD44^+^ T cells (gating within CD4 + T cells), CXCR5^+^CD4^+^ T cells, and CCR7^*lo*^ CXCR5^+^ T cells (gating within CD4 + T cells). The percentage of four subsets of CD4^+^T cells. One way analysis of variance (ANOVA). **(E)** The percentage of four subsets of CD4 + T cells after 30, 60, and 90 days of immunization. **(F,G)** Gating strategy for the analysis of CXCR5^+^CD4^+^ T cell subsets and the percentage of Bcl-6^+^ and IL-21^+^ cells within CXCR5^+^ and CXCR5^-^CD4^+^ T cell compartments after 90 days of immunization. Paired *t*-test. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, and \*\*\*\**P* \< 0.0001.](fimmu-11-00701-g001){#F1}

IFN-α Enhances Chemokine Receptor Expression by Memory Tfh Cells Following Recombinant Adenoviral Exposure {#S3.SS2}
----------------------------------------------------------------------------------------------------------

We next assessed the expression of other chemokine receptors at the surface of memory Tfh cells. We monitored the expression of the chemokine receptors CXCR3 and CCR6, whose differential expression defines the following Tfh cell subsets: cTfh1 (CXCR3^+^CCR6^--^), cTfh2 (CXCR3^--^CCR6^--^), and cTfh17 (CXCR3^--^CCR6^+^) ([Figure 2A](#F2){ref-type="fig"}). We found that the proportions of cTfh1 and cTfh2, but not cTfh17, cells were significantly increased in mice immunized with recombinant adenoviruses ([Figure 2B](#F2){ref-type="fig"}). The results reveal that IFN-α enhances the generation of cTfh1 and cTfh2 memory Tfh cell subtypes following recombinant adenoviral exposure.

![IFN-α enhances chemokine receptor expression by memory Tfh cells. **(A)** Gating strategy for the analysis of CXCR3 and CCR6 among of CXCR5^+^CD4^+^ T cells. **(B)** The percentage of CXCR3^+^CCR6^-^, CXCR3^-^CCR6^-^, and CXCR3^-^CCR6^+^ T cells within CXCR5^+^CD4^+^ T cell compartments after 90 days of immunization. One way analysis of variance (ANOVA). \**P* \< 0.05.](fimmu-11-00701-g002){#F2}

IFN-α Enhances Memory B Cell Generation Following Recombinant Adenoviral Exposure {#S3.SS3}
---------------------------------------------------------------------------------

To test whether memory B cell numbers correlated with those of memory Tfh cells, we analyzed memory B cells on days 30, 60, and 90 after immunization. Consistently, the proportion of memory B cells and IgG1 levels were significantly increased in mice immunized with recombinant adenoviruses, which was sustained for at least 90 days following immunization ([Figures 3A--C](#F3){ref-type="fig"}). The result reveal that IFN-α enhances the generation of memory B cells induced by recombinant adenoviruses. CD86^+^ memory B cells can become antibody-secreting effector plasma cells after rechallenge with antigen. We therefore also checked CD86 expression on memory B cells in addition to their antibody production capacity, and found that they rapidly upregulated both functions after rechallenge with antigen ([Figures 3D,E](#F3){ref-type="fig"}).

![IFN-α enhances memory B cell generation. **(A,B)** Thirty days after the immunization, representative dot plot from flow cytometric analysis of B220^+^CD38^+^ B cells and IgG1^+^GL-7^-^ B cells. The percentage of two cells. One way analysis of variance (ANOVA). **(C)** The percentage of two subsets of B cells after 30, 60, and 90 days of immunization. **(D)** Representative dot plot from flow cytometric analysis of CD86^+^ B cells. The percentage of CD86^+^ B cells among of B220^+^CD38^+^ B cells before and after rechallenge. Paired *t*-test. **(E)** Serum levels of total IgG, IgG1, IgG2a, and IgG2b were analyzed by ELISA. Paired *t*-test. \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001.](fimmu-11-00701-g003){#F3}

IFN-α Enhances the Memory Tfh Cell Numbers Contributing to Recall Responses Following Subsequent Antigen Challenge {#S3.SS4}
------------------------------------------------------------------------------------------------------------------

To investigate whether long-lived memory Tfh cells can contribute to recall responses following subsequent antigen challenge, we analyzed CD4^+^ T cells and Tfh memory cells 3 days after their reactivation *in vivo*. We found that IFN-α enhanced memory Tfh cell activation after rechallenge with antigen. Upon rechallenge with FMD recombinant adenoviral vaccines, memory Tfh cells once again rapidly upregulated their signature Bcl-6 and CXCR5 markers, which were both strongly downregulated in the resting memory phase ([Figures 4A--D](#F4){ref-type="fig"}). Thus, these data demonstrate that Bcl-6 is induced at a much earlier timepoint in the memory Tfh cell response than in naïve T cells, and that this rapid Bcl-6 upregulation correlates well with IL-21 expression ([Figure 4E](#F4){ref-type="fig"}). Besides IL-21, we also measured the intracellular production of IL-4 and IFN-γ by memory Tfh cells 3 days after antigenic restimulation, and found that these were also rapidly upregulated ([Figure 4E](#F4){ref-type="fig"}).

![IFN-α enhances the memory Tfh cell numbers contributing to recall responses following subsequent antigen challenge. **(A--D)** Representative dot plot from flow cytometric analysis of CD44^+^CD4^+^ T cells, CD62L^-^CD44^+^ T cells (gating within CD4 + T cells), CXCR5^+^CD4^+^ T cells, and CXCR5^+^Bcl-6^+^ T cells (gating within CD4 + T cells). The percentage of four subsets of CD4 + T cells before and after rechallenge. **(E)** Representative dot plot from flow cytometric analysis of IL-21^+^, IL-4^+^ and IFN-γ^+^ T cells. The percentage of IL-21^+^, IL-4^+^, and IFN-γ^+^ T cells among of CXCR5^+^CD4^+^ T cells before and after rechallenge. Paired *t*-test. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, and \*\*\*\**P* \< 0.0001.](fimmu-11-00701-g004){#F4}

IFN-α Enhances Memory Tfh Cell Formation, Potentially by Regulating the Transcription Factors Bcl-6 and STAT1 {#S3.SS5}
-------------------------------------------------------------------------------------------------------------

As Bcl-6 is a master regulator of Tfh cell generation, we checked Bcl-6 mRNA levels, and found that they consistently upregulated after rechallenge with antigen ([Figure 5A](#F5){ref-type="fig"}). STAT1 acts as an important Tfh cell transcription factor, and directly regulates the expression of Bcl-6. We also observed STAT1 upregulation after rechallenge with antigen ([Figure 5B](#F5){ref-type="fig"}). These data indicate that IFN-α enhances memory Tfh cell differentiation potentially by regulating the transcription factors Bcl-6 and STAT1.

![IFN-α enhances memory Tfh cell formation, potentially by regulating the transcription factors Bcl-6 and STAT1. **(A,B)** Bcl-6 and STAT1 mRNA was measured and normalized simultaneously with mouse β-actin endogenous controls by quantitative Real-Time PCR before and after rechallenge. Paired *t*-test. \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001.](fimmu-11-00701-g005){#F5}

Discussion {#S4}
==========

The success of most vaccines relies on the generation of antibodies to provide protection against subsequent infection. Antibody affinity maturation and the generation of B cell memory occur within the specialized GC microenvironment within the B cell follicles of secondary lymphoid organs ([@B18]). Tfh cells provide growth and differentiation signals to GC B cells and mediate the positive selection of high-affinity B cell clones in the GC, thereby determining which B cells exit the GC as plasma cells and memory B cells ([@B19]--[@B21]). Because of their central role in the production of long-lasting humoral immunity, Tfh cells represent an interesting target for rational vaccine design. Strategies aiming to augment Tfh cell numbers may therefore represent a rational approach to enhancing vaccine responses. Overall, subcutaneous immunization promotes the development of memory Tfh cells ([@B15], [@B17]). Our previous study has shown that the numbers of Tfh cells and GC B cells positively correlate, as do the numbers of memory Tfh cells after FMDV recombinant adenoviral vaccination in the present study. We have also previously demonstrated that IFN-α could enhance the numbers of Tfh cells, GC B cells, and memory Tfh cells.

Upon rechallenge with FMD recombinant adenoviral vaccines, Tfh cells rapidly upregulate their signature Bcl- 6 and CXCR5 markers, which are otherwise strongly downregulated in the resting memory phase ([@B7], [@B8]). Here we have shown that IFN-α could enhance the expression of these molecules and promote memory Tfh activation after rechallenge with antigen. Taken together, these data demonstrate that Bcl-6 is induced at a much earlier timepoint in memory Tfh cell activation than in naïve T cells, and that this rapid Bcl-6 upregulation correlates well with IL-21 expression. Here, we were also surprised to discover that IFN-α enhances the differentiation of cTfh1 and cTfh2, but not cTfh17 cell subsets. Some studies have implied that the CCR7^*lo*^ Tfh cell subset provides a biomarker for monitoring protective antibody responses during infection or vaccination, and pathogenic antibody responses in autoimmune disease ([@B22]). We have shown that FMDV recombinant adenoviruses could induce generation of CCR7^*lo*^CXCR5^+^CD4^+^ T cells, while IFN-α enhanced the numbers of these cells. These data indicate that IFN-α administration could represent an effective strategy for the generation of CCR7^*lo*^ memory Tfh cells to enhance vaccine responses.

Many cytokines that drive helper T cell specification bind type I/II cytokine receptors, which activate the JAK/STAT signaling pathway, culminating in effector cell differentiation ([@B23], [@B24]). Previous studies have shown the direct effects of type I IFNs on Tfh differentiation, by inducing Bcl-6 upregulation and promoting CXCR5 expression ([@B14]). The ability of IFN-α/β to drive these Tfh cell features was entirely STAT1-dependent, which binds directly at the Bcl-6 locus ([@B25]). The results of the present study also confirm the above findings.

Another study has shown that in these recall responses, antigen-specific memory B cells greatly contribute to the rapid induction of Bcl-6 and IL-21 in memory Tfh cells ([@B26]). Here, we have demonstrated that IFN-α also enhances the generation of memory B cells, IgG1 memory B cells, and the production of antibodies induced by recombinant adenoviruses. Studie has shown that IgG1 memory B cells are more likely to differentiate into plasma cells than IgM memory B cells or naive cells ([@B27]). Furthermore, their proliferation and differentiation into plasma cells may require direct T cell/B cell interactions. Some reports have found that CD4^+^ T cells are close to contracted GC on the 60th day and are present in the vicinity of IgG1 memory B cells. It is speculated that long-lived memory Tfh cells that make up a portion of these CD4^+^ T cells, are mainly responsible for activating IgG1 memory B cells ([@B28]). After antigen re-exposure, memory B cells develop into short-lived effectors capable of rapid antibody production. In addition, memory B cells reenter GCs, resulting in the generation of affinity-matured long-lived plasma cells (LLPCs) and memory B cells. This process depends on costimulation and cytokine production by Tfh cells. As a general rule in mice, IFN-γ^+^ Tfh cells can be found in conjunction with IgG2a^+^ B cells, whereas IL-4^+^ Tfh cells were more likely to be paired with IgG1^+^ B cells ([@B29]--[@B31]). Here, we have shown that IFN-α enhances both IFN-γ^+^ Tfh cells and IL-4^+^ Tfh cells activity. IFN-α also enhances CD86 expression in memory B cells before they become antibody-secreting effector plasma cells. CD86 is then rapidly upregulated on these cells after rechallenge with antigen. Increased antigen presentation by B cells also increases the capacity of Tfh cells to produce the cytokines IL-4 and IL-21. An enhanced potential to produce IL-21, paired with higher CXCR5 and lower CCR7 expression levels, should therefore enable memory Tfh cells to provide more efficient help for antigen-specific B cells than their non-Tfh counterparts ([@B32]).

Our results demonstrate that memory Tfh cells can survive for long periods and are rapidly reactivated, upon FMDV recombinant adenoviral recall, to differentiate into effector Tfh cells. It has been shown that this step is dependent on memory B cells, suggesting that memory B cells may directly activate memory Tfh cells in the follicle ([@B32]). It is generally accepted that CXCR5^+^ memory Tfh cells preferentially home to the T-B border and the follicle to provide help to B cells ([@B33]). In agreement with these findings, we found that IFN-α could also enhance memory B cell-mediated immunity. Based on these data, we propose a strategy whereby IFN-α could enhance the anti-FMD recombinant adenoviral immune response by promoting cognate interactions between memory Tfh and memory B cells, with important implications for the development of better vaccines.
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